State of the Art Corneal Ulcer Treatment:

The Eye Show · EyeDoc2020 · Clinical Frontier

🔬 Nanocarrier-Based Anti-Infectives:
A New Frontier in Corneal Ulcer Therapy

Why less than 5% of your eye drop reaches its target — and how nanotechnology is about to revolutionize how we treat corneal infections.

👁️ Sandra Lora Cremers, MD, FACS
Ophthalmologist · Johns Hopkins/Suburban Hospital

```

Bacterial keratitis — commonly known as corneal ulcer — remains one of the most challenging ophthalmic emergencies we face in clinical practice. Despite decades of antibiotic development, the fundamental problem persists: how do we effectively deliver antimicrobial agents to the site of infection when the eye's natural defenses actively work against us?

The answer may lie in nanotechnology. Over the past several years, researchers have been developing sophisticated nanocarrier systems that promise to revolutionize how we treat corneal infections. These aren't just incremental improvements — they represent a paradigm shift in ocular drug delivery.

<5%

Drug reaching intraocular structures<sup>[1,2]</sup>

2–3 min

Tear turnover clearing your drops<sup>[1,3]</sup>

6 hrs

Retention with nanoparticles<sup>[6]</sup>

2.6×

Longer corneal half-life vs Vigamox®<sup>[13]</sup>

· · · · ·

💧 The Problem with Conventional Eye Drops

Let's start with a sobering statistic: less than 5% of a topically applied drug actually reaches intraocular structures.<sup>[1,2]</sup> Think about that for a moment. When we prescribe hourly antibiotic drops for bacterial keratitis, we're achieving single-digit bioavailability at best.

"The limited volume capacity of the cul-de-sac (~30 μL) means that most of a standard 50 μL eye drop is immediately expelled."

AAPS PharmSciTech, 2021 <sup>[3]</sup>

The eye has evolved multiple sophisticated barriers:

💧

Precorneal Barriers

Rapid tear turnover every 2–3 minutes, nasolacrimal drainage, and blink reflex rapidly clear drugs from the ocular surface.<sup>[1,3]</sup>

🛡️

Corneal Barriers

Tight junctional complexes restrict paracellular transport. The tri-layered cornea creates alternating lipophilic/hydrophilic regions — a pharmaceutical paradox.<sup>[2,3,4]</sup>

⚗️

Biochemical Barriers

Efflux transporters, enzymatic degradation, and drug binding to tear proteins and melanin all reduce effective drug concentration.<sup>[3,5]</sup>

· · · · ·

🧬 How Nanocarriers Overcome Ocular Barriers

⏱ Enhanced Corneal Retention

Mucoadhesive nanoparticles extend ocular retention from minutes to approximately 6 hours<sup>[6]</sup> via surface modifications with chitosan, hyaluronic acid, or alginate binding to the mucin layer of the tear film.<sup>[7,8]</sup>

🔬 Improved Corneal Penetration

Particles in the 100–250 nm range demonstrate optimal uptake by corneal epithelial cells.<sup>[9]</sup> Active internalization via caveolae-mediated endocytosis, clathrin-mediated endocytosis, and macropinocytosis bypasses tight junctions.<sup>[9,10]</sup> Positively charged nanoparticles show superior penetration.<sup>[11]</sup>

💊 Sustained Drug Release

Controlled, sustained release maintains therapeutic drug levels while reducing dosing frequency.<sup>[12,13]</sup> Critical for treating biofilm-associated infections requiring prolonged antibiotic exposure.

🎯 Bacterial Targeting

Surface modifications with phenylboronic acid groups enable specific binding to diol-containing bacterial cell walls, enhancing drug internalization directly into pathogens.<sup>[14]</sup>

· · · · ·

📄 Evidence from Preclinical Studies

ACS Applied Materials & Interfaces · 2024

Ciprofloxacin-Loaded Glycol Chitosan Nanoparticles

Beyond simple drug delivery, these nanoparticles demonstrated antiquorum sensing properties — disrupting bacterial communication systems that coordinate biofilm formation and virulence. In vivo results: effective reduction in corneal opacity and bacterial load, with ~6-hour ocular retention, inhibiting acyl homoserine lactones, pyocyanin, and bacterial motility.<sup>[6]</sup>

Journal of Controlled Release · 2025

Moxifloxacin-Loaded Gelatin Nanoparticles

Gelatin methacryloyl nanoparticles in hyaluronic acid matrix achieved a 2.6-fold longer corneal half-life vs. commercial Vigamox®. Dual efficacy in both preventing and treating established bacterial keratitis, with reduced corneal opacity and decreased bacterial counts.<sup>[13]</sup>

Biomacromolecules · 2023

Multifunctional Polymer Vesicles

Combining antibiotic delivery with reactive oxygen species (ROS) scavenging — ciprofloxacin plus thioether moieties neutralizing ROS at inflammatory sites. This dual antibiotic-antioxidant strategy addresses both bacterial eradication and tissue protection from oxidative damage.<sup>[15]</sup>

Pharmaceutics · 2025

Invasomes + N-Acetylcysteine for Pseudomonas Keratitis

NAC disrupts biofilm structure while invasomes deliver high-concentration ceftazidime directly to bacteria. Rapid eradication confirmed by microbiological, histopathological, and immunohistopathological examination in P. aeruginosa keratitis model.<sup>[16]</sup>

Journal of Materials Chemistry B · 2022

ROS-Scavenging Glyco-Nanoplatform

Glycopolymeric micelles with levofloxacin, chondroitin sulfate, and phenylboronic acid groups serving triple duty: epithelial penetration + bacterial anchorage + antioxidant activity. Effectively cured S. aureus keratitis within 5 days in rat model.<sup>[17]</sup>

· · · · ·

🚀 Advanced Nanocarrier Strategies

📡

Condition-Responsive Release

Protease-degradable gelatin nanoparticles release antifungals proportional to infection severity — a self-regulating pharmacological response.<sup>[18]</sup>

💡

Photodynamic Therapy

Maltodextrin-driven MOF nanoparticles specifically target bacteria and enhance photodynamic therapy efficacy — critical for antibiotic-resistant keratitis.<sup>[19,20]</sup>

🪡

Dissolving Microneedle Patches

Graphene quantum dot patches penetrate the corneal epithelial layer, delivering antimicrobials directly into the stroma. Resolved S. aureus keratitis in 7 days with minimal invasiveness.<sup>[21]</sup>

· · · · ·

⚠️ The Clinical Translation Gap

Despite these promising preclinical results, we must acknowledge a critical limitation: clinical trials demonstrating efficacy and safety in human patients are largely absent.<sup>[12]</sup>

⚡ Key Challenges to Clinical Translation

Manufacturing scalability — lab synthesis must meet GMP standards  |  Long-term stability — avoiding aggregation and degradation  |  Regulatory complexity — combination product classification  |  Cost-effectiveness — improved outcomes must justify added complexity

"The question is not whether these technologies will reach clinical practice, but when — and which formulations will prove most effective."

— Sandra Lora Cremers, MD, FACS

· · · · ·

✅ Conclusion

Nanocarrier-based anti-infectives represent a genuine paradigm shift in corneal ulcer therapy. By addressing the fundamental limitations of conventional eye drops — poor bioavailability, rapid clearance, and limited corneal penetration — these systems offer the potential for more effective treatment with reduced dosing frequency and improved patient compliance.

The preclinical evidence is robust: superior antimicrobial efficacy, enhanced corneal penetration, prolonged retention, and additional benefits like biofilm disruption, ROS scavenging, and targeted delivery. The convergence of nanotechnology, materials science, and ophthalmology is opening new possibilities for treating one of our most challenging clinical problems. For patients suffering from corneal ulcers, that convergence can't come soon enough.

🎧 👁️

Listen to The Eye Show Podcast

For more cutting-edge ophthalmology insights from Dr. Sandra Cremers — available on Apple Podcasts & Spotify

EyeDoc2020.blogspot.com  |  The Eye Show  |  @sandracremersmd

📚 References

1. Awwad S, et al. Principles of Pharmacology in the Eye. Br J Pharmacol. 2017;174(23):4205–4223.
2. Sánchez-López E, et al. Lipid Nanoparticles (SLN, NLC): Overcoming the Anatomical and Physiological Barriers of the Eye. Eur J Pharm Biopharm. 2017;110:70–75.
3. Lanier OL, et al. Review of Approaches for Increasing Ophthalmic Bioavailability. AAPS PharmSciTech. 2021;22(3):107.
4. Shafiq M, et al. An Insight on Ophthalmic Drug Delivery Systems. J Control Release. 2023;362:446–467.
5. Ahmed S, et al. Ocular Drug Delivery: A Comprehensive Review. AAPS PharmSciTech. 2023;24(2):66.
6. Padaga SG, et al. Glycol Chitosan-Poly(lactic Acid) Conjugate Nanoparticles Encapsulating Ciprofloxacin. ACS Appl Mater Interfaces. 2024;16(15):18360–18385.
7. Mahaling B, Katti DS. Understanding the Influence of Surface Properties of Nanoparticles. Int J Pharm. 2016;501(1-2):1–9.
8. Almeida H, et al. Nanoparticles in Ocular Drug Delivery Systems for Topical Administration. Curr Pharm Des. 2015;21(36):5212–24.
9. Azadi M, David AE. Enhancing Ocular Drug Delivery. ACS Biomater Sci Eng. 2024;10(1):429–441.
10. Nagai N, et al. Energy-Dependent Endocytosis Is Responsible for Drug Transcorneal Penetration. Int J Nanomedicine. 2019;14:1213–1227.
11. De Hoon I, et al. Influence of the Size and Charge of Carbon Quantum Dots on Corneal Penetration. ACS Appl Mater Interfaces. 2023;15(3):3760–3771.
12. Polat HK, et al. Novel Drug Delivery Systems to Improve the Treatment of Keratitis. J Ocul Pharmacol Ther. 2022;38(6):376–395.
13. Zheng Y, et al. Naturally Derived Mucoadhesive Nanosuspension. J Control Release. 2025:114046.
14. Zhang Y, et al. Epithelium-Penetrable Nanoplatform With Enhanced Antibiotic Internalization. Biomacromolecules. 2021;22(5):2020–2032.
15. Chen Q, et al. Multifunctional Polymer Vesicles for Synergistic Antibiotic-Antioxidant Treatment. Biomacromolecules. 2023;24(11):5230–5244.
16. Josef M, et al. Invasomes and NLC for Targeted Delivery of Ceftazidime Combined With NAC. Pharmaceutics. 2025;17(9):1184.
17. Zhang Y, et al. ROS-scavenging Glyco-Nanoplatform for Synergistic Antibacterial Therapy. J Mater Chem B. 2022;10(24):4575–4587.
18. Ahsan SM, Rao CM. Condition Responsive Nanoparticles for Managing Infection and Inflammation in Keratitis. Nanoscale. 2017;9(28):9946–9959.
19. Han H, et al. Biofilm Microenvironment Activated Supramolecular Nanoparticles. J Control Release. 2020;327:676–687.
20. Chen L, et al. Maltodextrin-Driven MOF Nano-Antibacterial System for Bacterial Keratitis. J Control Release. 2025;380:1164–1183.
21. Fang Y, et al. Graphene Quantum Dot-Based Dissolving Microneedle Patches for Bacterial Keratitis. Int J Pharm. 2023;639:122945.
22. Mobaraki M, et al. Biodegradable Nanoparticle for Cornea Drug Delivery. Pharmaceutics. 2020;12(12):E1232.
23. Bazán Henostroza MA, et al. Antibiotic-Loaded Lipid-Based Nanocarrier. Int J Pharm. 2022;621:121782.
24. Jani K, et al. Focused Insights Into Liposomal Nanotherapeutics. Curr Med Chem. 2025;32(34):7577–7595.
25. Yang Y, Lockwood A. Topical Ocular Drug Delivery Systems: Innovations for an Unmet Need. Exp Eye Res. 2022;218:109006.

```

Sandra Lora Cremers, MD, FACS
Ophthalmologist · Visionary Eye Doctors · Johns Hopkins/Suburban Hospital
EyeDoc2020.blogspot.com  ·  The Eye Show Podcast  ·  amazon.com/shop/sandracremersmd